Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.

United States - English - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (propiolactone inactivated) (unii: 6f59dl4eet) (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:qwb7m7p3k9), influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) antigen (propiolactone inactivated) (unii: y9cjf75rbv) (influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:lw2jc76p6m), influenza b virus b/victoria/705/2 - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11] ) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - influenza virus haemagglutinin type a/bayern/7/95-like h1n1 15ug; influenza virus haemagglutinin type a/sydney/5/97-like h3n2 15ug; influenza virus haemagglutinin type b/beijing/184/93-like 15ug - suspension for injection - active: influenza virus haemagglutinin type a/bayern/7/95-like h1n1 15ug influenza virus haemagglutinin type a/sydney/5/97-like h3n2 15ug influenza virus haemagglutinin type b/beijing/184/93-like 15ug excipient: dibasic sodium phosphate monobasic potassium phosphate sodium chloride water for injection

European Union - English - EMA (European Medicines Agency)

ceva santé animale - inactivated influenza-a virus / swine - immunologicals - pigs - active immunisation of pigs from the age of 56 days onwards, including pregnant sows, against swine influenza caused by subtypes h1n1, h3n2 and h1n2 to reduce clinical signs and viral lung load after infection.onset of immunity: 7 days after primary vaccinationduration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and 6 months in pigs vaccinated for the first time at 96 days and above.active immunisation of pregnant sows after finished primary immunisation by administration of a single dose 14 days prior to farrowing to develop high colostral immunity, which provides clinical protection of piglets for at least 33 days after birth.

Canada - English - Health Canada

seqirus uk limited - haemagglutinin-strain a (h1n1); haemagglutinin-strain a (h3n2); haemagglutinin-strain b - suspension - 15mcg; 15mcg; 15mcg - haemagglutinin-strain a (h1n1) 15mcg; haemagglutinin-strain a (h3n2) 15mcg; haemagglutinin-strain b 15mcg - vaccines

Canada - English - Health Canada

seqirus uk limited - haemagglutinin-strain a (h1n1); haemagglutinin-strain a (h3n2); haemagglutinin-strain b - suspension - 15mcg; 15mcg; 15mcg - haemagglutinin-strain a (h1n1) 15mcg; haemagglutinin-strain a (h3n2) 15mcg; haemagglutinin-strain b 15mcg - vaccines

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) (unii: 5i5hvc73i8) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) - unii:euj84un96z) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. do not administer influenza a (h1n1) 2009 monovalent vaccine to anyone with a known severe hypersensitivity to egg proteins or any component of the vaccine or life-threatening reactions after previous administration of any influenza vaccine. [see warnings and precautions (5) and description (11) ] sanofi pasteur's influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluzone vaccine) are manufactured by the same process. available information for fluzone vaccine is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluzone vaccine. it is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction

Philippines - English - FDA (Food And Drug Administration)

ulivaccines, inc. - influenza vaccine (surface antigen, inactivated) 2019-2020 northern hemisphere strains - suspension for injection - formulation: each dose (0.5 ml) contains the following strains*: a/brisbane/02/2018 (h1n1) pdm09-like strain (a/brisbane/02

Philippines - English - FDA (Food And Drug Administration)

ulivaccines, inc. - influenza vaccine (surface antigen, inactivated) 2019-2020 northern hemisphere strains - suspension for injection im - formulation: each dose (0.25 ml) contains the following strains*: a/brisbane/02/2018 (h1n1) pdm09-like strain (a/brisbane/0

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - a/california/07/2009 (h1n1)v a/brisbane/59/2007 (h1n1) - like strain (a/brisbane/59/2007, ivr-148) ph.eur b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15,15,15 microgram